John Kastelein

John Kastelein

Net worth: 1 M $ as of 2026-09-29

72 year
Health Technology
Health Services
Consumer Services

Profile

Dr. John J.
Kastelein is a Non-Executive Director & Chief Scientific Officer at NewAmsterdam Pharma Co. NV, a Chief Scientific Officer & Executive Director at NewAmsterdam Pharma Corp., a Chief Scientific Officer & Executive Director at NewAmsterdam Pharma Holding BV, a Chief Medical Officer at Staten Biotechnology BV, a Chief Executive Officer at Vascular Research Network B V, a Chairman-Vascular Medicine Department at Academisch Medisch Centrum, an Emeritus Professor-Medicine at University of Amsterdam, an Operating Partner at Forbion Capital Partners Management Holding BV, a President at Dutch Atherosclerosis Society and a President- National Scientific Committee at Familial Hypercholesterolemia Foundation.
He is on the Board of Directors at NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Corp., NewAmsterdam Pharma Holding BV, NorthSea Therapeutics BV and Oxitope Pharma BV.
He received his undergraduate degree from the University of Amsterdam and a doctorate degree from the University of Amsterdam.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-09-29 53,500 ( 0.04% ) 1 M $ 2026-09-29

John Kastelein active positions

CompaniesPositionStart
FRAZIER LIFESCIENCES ACQUISITION CORPORATION Chief Tech/Sci/R&D Officer 2022-10-31
Corporate Officer/Principal -
Founder 2018-12-31
Director/Board Member -
Private Equity Investor 2018-12-31
Chief Tech/Sci/R&D Officer 2017-12-31
Director/Board Member -
Corporate Officer/Principal -
Dutch Atherosclerosis Society
President -
░░░░░░░░ ░░░░░░░░ ░░░░░░░ ░ ░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░

Education of John Kastelein

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

65

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Services

Consumer Services

Finance

Dutch Atherosclerosis Society

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Vascular Research Network B V

  1. Stock Market
  2. Insiders
  3. John Kastelein